Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19

Summary

To evaluate the safety and preliminary efficacy of efzofitimod, compared to placebo matched to efzofitimod, in hospitalized participants with SARS-CoV-2 (COVID-19) severe pneumonia not requiring mechanical ventilation.

Timeline

Start

2020-06-04

Primary completion

2020-10-23

Completion

2020-10-23

Outcome

Met primary endpoint

release “The trial met its primary endpoint of safety, demonstrating that a single, intravenous (IV) dose of ATYR1923 was generally safe” atyrpharma.com ↗

release “The study met its primary safety endpoint and demonstrated a signal of activity through clinical improvement in the 3.0 mg/kg cohort compared to placebo.” atyrpharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efzofitimod	Unknown	1 mg/kg	Intravenous
Subject	Efzofitimod	Unknown	3 mg/kg	Intravenous

Indications